Form D · Pharmaceuticals
NBO Pharma Inc.
Bedford, NY · CIK 0002103906
Offering snapshot reported Nov 9, 2026 · SEC filing
- Reported sold
- $238K Offering amount: $7M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 2, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 9, 2026 | Initial | $238,000 | No comparison | 5 | SEC filing |
| Jan 22, 2026 | Initial | $7,640,217 | No comparison | 93 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06c
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $960K
- Finders' fees
- $0
- Form D file number
- 021-604113
Issuer will provide placement agent (i) 13% of gross proceeds received from qualifying investors, (ii) a $50,000 expense fee, and (iii) 15% PA warrant coverage. Commissions estimate assumes full $7MM offering amount is sold to qualifying investors.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Paulson Investment Company, LLC | 5670 |
Source: Form D, filed Nov 9, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Colin Foster | Director |
| Robert Friedman | Director |
| Bard Geesaman | Director |
| Fredric David Price | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
64 Quarry Lane
Bedford, NY, 10506
Bedford, NY, 10506